Details about Bonny Parkinson

Access statistics for papers by Bonny Parkinson.

Last updated 2022-09-01. Update your information in the RePEc Author Service.

Short-id: ppa1146

Working Papers

2013

1. Pharmaceutical policy in Australia. CHERE Working Paper 2013/01
   Working Papers, CHERE, University of Technology, Sydney

2012

2. Measuring the loss of consumer choice in mandatory health programs using Discrete Choice Experiments. CHERE Working Paper 2012/04
   Working Papers, CHERE, University of Technology, Sydney

Journal Articles

2022

1. An examination of machine learning to map non‐preference based patient reported outcome measures to health state utility values
   Health Economics, 2022, 31, (8), 1525-1557
2. Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in Australia
   PharmacoEconomics, 2022, 40, (8), 807-821
3. The cost-effectiveness of unilateral cochlear implants in UK adults
   The European Journal of Health Economics, 2022, 23, (5), 763-779

2019

4. Correction to: Economic Evaluations of Childhood Hearing Loss Screening Programmes: A Systematic Review and Critique
   Applied Health Economics and Health Policy, 2019, 17, (3), 419-419
5. Economic Evaluations of Childhood Hearing Loss Screening Programmes: A Systematic Review and Critique
   Applied Health Economics and Health Policy, 2019, 17, (3), 331-357
6. Is Reclassification of the Oral Contraceptive Pill from Prescription to Pharmacist-Only Cost Effective? Application of an Economic Evaluation Approach to Regulatory Decisions
   PharmacoEconomics, 2019, 37, (8), 1049-1064

2018

7. The Real-World Cost-Effectiveness of Coronary Artery Bypass Surgery Versus Stenting in High-Risk Patients: Propensity Score-Matched Analysis of a Single-Centre Experience
   Applied Health Economics and Health Policy, 2018, 16, (5), 661-674

2016

8. Authors’ Reply to Palozzo and Messori: ‘‘Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review’’
   PharmacoEconomics, 2016, 34, (4), 421-422
9. Real-World Evidence: A Comparison of the Australian Herceptin Program and Clinical Trials of Trastuzumab for HER2-Positive Metastatic Breast Cancer
   PharmacoEconomics, 2016, 34, (10), 1039-1050 View citations (1)

2015

10. Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review
    PharmacoEconomics, 2015, 33, (9), 905-924 View citations (14)

2014

11. Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique
    The European Journal of Health Economics, 2014, 15, (1), 93-112 View citations (2)

2013

12. Measuring the Loss of Consumer Choice in Mandatory Health Programmes Using Discrete Choice Experiments
    Applied Health Economics and Health Policy, 2013, 11, (2), 139-150 View citations (2)

2011

13. Considering consumer choice in the economic evaluation of mandatory health programmes: A review
    Health Policy, 2011, 101, (3), 236-244 View citations (2)
14. Integrating Health Economics Into the Product Development Cycle
    Medical Decision Making, 2011, 31, (4), 596-610 View citations (2)